Johnson & Johnson Reports Strong Q1 2026 Results Amid Drug Pricing Agreement, Raises Full-Year Guidance

According to the Zhitong Finance APP, Johnson & Johnson (JNJ.US) reported first-quarter sales that exceeded market expectations and raised its full-year guidance, mainly due to strong growth in sales of new cancer and depression drugs.

Earnings Report Shows Johnson & Johnson's Q1 Sales Increased by 9.9% Year-over-Year to $24.1 Billion, Beating Market Expectations; Adjusted Earnings Per Share at $2.70 Also Exceeded Market Expectations.

Johnson & Johnson now expects full-year sales to be between $100.3 billion and $101.3 billion, up from the previously expected range of $100 billion to $101 billion. The company also forecasts adjusted earnings per share to be between $11.45 and $11.65, higher than the prior expectation of $11.43 to $11.63.

Johnson & Johnson's quarterly results are released ahead of its competitors and are considered an industry bellwether. The robust Q1 financial report from Johnson & Johnson indicates that despite the company and its competitors reaching an agreement with the White House to lower prices for some medications, these large pharmaceutical enterprises have maintained a healthy growth momentum.

Johnson & Johnson CFO Joseph Wolk described the earnings report as "a very good start." He noted that the company had front-loaded some of its annual expenses for sales and advertising campaigns tied to several new brands. These include Tremfya, used for treating autoimmune diseases, and Caplyta, recently acquired for mental health conditions. Johnson & Johnson hopes the increased spending will directly translate into higher sales.

The company has also established a dedicated sales team for its newly launched psoriasis drug, Icotyde. The drug received approval from U.S. regulators last month. Wolk stated that the drug is "still in its early stages, but market demand is very strong."

Wolk stated that Johnson & Johnson is expected to remain unaffected by the new round of pharmaceutical tariffs announced earlier this month, as the company reached an agreement with the Trump administration to offer drug discounts. He mentioned, "In the latest round of tariff policies, we are not a target of the government."

Due to the expiration of patents for some older drugs, Johnson & Johnson is striving to boost the sales of new drugs, leading to an increase in sales and marketing expenses in the first quarter.

Sales of multiple targeted anticancer drugs have achieved steady growth, especially the blockbuster drug Daratumab (Darzalex) for treating multiple myeloma. Rybrevant and Lazcluze, two lung cancer drugs typically used in combination, saw their sales increase by nearly 83% in the first quarter, although they account for a smaller portion of Johnson & Johnson's product portfolio.

Besides cancer treatments, Johnson & Johnson has several other rapidly growing new drugs. In the first quarter, sales of Spravato, a fast-acting treatment for refractory depression, increased by more than 46%.

Johnson & Johnson is also focusing on rapidly growing products in its medical device sector and has announced plans to spin off its orthopedics division. Medical device sales grew by 7.7% in the first quarter.

Johnson & Johnson's stock price fell 1.66% in pre-market trading after the earnings report was released.